Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Absence of LTB4/BLT1 axis facilitates generation of mouse GM-CSF-induced long-lasting antitumor immunologic memory by enhancing innate and adaptive immune systems.
Yokota Y, Inoue H, Matsumura Y, Nabeta H, Narusawa M, Watanabe A, Sakamoto C, Hijikata Y, Iga-Murahashi M, Takayama K, Sasaki F, Nakanishi Y, Yokomizo T, Tani K. Yokota Y, et al. Among authors: tani k. Blood. 2012 Oct 25;120(17):3444-54. doi: 10.1182/blood-2011-10-383240. Epub 2012 Aug 30. Blood. 2012. PMID: 22936657 Free article.
TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
Narusawa M, Inoue H, Sakamoto C, Matsumura Y, Takahashi A, Inoue T, Watanabe A, Miyamoto S, Miura Y, Hijikata Y, Tanaka Y, Inoue M, Takayama K, Okazaki T, Hasegawa M, Nakanishi Y, Tani K. Narusawa M, et al. Among authors: tani k. Cancer Immunol Res. 2014 Jun;2(6):568-80. doi: 10.1158/2326-6066.CIR-13-0143. Epub 2014 Apr 10. Cancer Immunol Res. 2014. PMID: 24830413
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.
Murahashi M, Hijikata Y, Yamada K, Tanaka Y, Kishimoto J, Inoue H, Marumoto T, Takahashi A, Okazaki T, Takeda K, Hirakawa M, Fujii H, Okano S, Morita M, Baba E, Mizumoto K, Maehara Y, Tanaka M, Akashi K, Nakanishi Y, Yoshida K, Tsunoda T, Tamura K, Nakamura Y, Tani K. Murahashi M, et al. Among authors: tani k. Clin Immunol. 2016 May;166-167:48-58. doi: 10.1016/j.clim.2016.03.015. Epub 2016 Apr 9. Clin Immunol. 2016. PMID: 27072896 Clinical Trial.
A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors.
Hijikata Y, Okazaki T, Tanaka Y, Murahashi M, Yamada Y, Yamada K, Takahashi A, Inoue H, Kishimoto J, Nakanishi Y, Oda Y, Nakamura Y, Tani K. Hijikata Y, et al. Among authors: tani k. PLoS One. 2018 Jan 2;13(1):e0187878. doi: 10.1371/journal.pone.0187878. eCollection 2018. PLoS One. 2018. PMID: 29293510 Free PMC article. Clinical Trial.
Non-transmissible MV Vector with Segmented RNA Genome Establishes Different Types of iPSCs from Hematopoietic Cells.
Hiramoto T, Tahara M, Liao J, Soda Y, Miura Y, Kurita R, Hamana H, Inoue K, Kohara H, Miyamoto S, Hijikata Y, Okano S, Yamaguchi Y, Oda Y, Ichiyanagi K, Toh H, Sasaki H, Kishi H, Ryo A, Muraguchi A, Takeda M, Tani K. Hiramoto T, et al. Among authors: tani k. Mol Ther. 2020 Jan 8;28(1):129-141. doi: 10.1016/j.ymthe.2019.09.007. Epub 2019 Sep 12. Mol Ther. 2020. PMID: 31677955 Free PMC article.
A pilot study to establish human T-cell leukemia virus type 1 (HTLV-1) carrier model using common marmoset (Callithrix jacchus).
Hirose L, Hiramoto T, Tian Y, Kohara H, Kobayashi S, Nagai E, Denda T, Tanaka Y, Ota Y, Jiyuan L, Miyamoto S, Miura Y, Hijikata Y, Soda Y, Inoue T, Okahara N, Itoh T, Sasaki E, Tojo A, Uchimaru K, Tani K. Hirose L, et al. Among authors: tani k. J Med Primatol. 2020 Apr;49(2):86-94. doi: 10.1111/jmp.12454. Epub 2020 Jan 12. J Med Primatol. 2020. PMID: 31930552
1,244 results